Nienke Z. Borren

Nienke Z. Borren

Auto-generated profile, based on publicly available information

Nienke Z. Borren

Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2018 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
NBNienke Z. Borren
Nienke Z. Borren
CWC. Janneke van der Woude
C. Janneke van der Woude
AAAshwin N. Ananthakrishnan
Ashwin N. Ananthakrishnan

5 January 2019 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
ALAlexander Levy
Alexander Levy
NBNienke Z. Borren
Nienke Z. Borren
BMBenjamin Maxner
Benjamin Maxner
WTWilliam Tan
William Tan
DBDanielle Bellavance
Danielle Bellavance
AAAshwin N. Ananthakrishnan
Ashwin N. Ananthakrishnan
The long-term natural history of microscopic colitis (MC) (collagenous colitis (CC), lymphocytic colitis (LC)), traditionally considered relapsing but non-progressive diseases, is poorly defined. Whether persistent histologic inflammation in such diseases is associated with an increased risk of colorectal neoplasia (CRN) or extracolonic cancers has not been robustly established. This retrospective cohort included diagnosed with MC at a referral center. Rates of CRN and extracolonic cancer were compared to patients undergoing screening colonoscopy (n = 306) and to the United States population using data from the Surveillance, Epidemiology, and End-Results (SEER) program. Standardized incidence ratios (SIR) and 95% confidence intervals were calculated and multivariable regression models used to identify the effect of MC diagnosis and severity on cancer risk. Our study included 221 patients with microscopic colitis (112 CC, 109 LC) among whom 77% were women. Compared to the colonoscopy control population, MC was associated with similar odds of tubular adenoma (Odds ratio (OR) 1.07, 95% CI 0.69–1.66) or villous adenoma (OR 1.26, 95% CI 0.17–9.42). Compared to patients with a single episode of MC, those with 2 or more episodes had similar risk of colon cancer (OR 0.83, 95% CI 0.20–3.39) or tubular adenoma (OR 1.49 95% CI 0.83–2.67). We also identified no statistical increase in the rates of cancer in the MC population compared to US-SEER data. Microscopic colitis was not associated with increased risk of CRN and extracolonic cancers when compared to controls undergoing colonoscopy or the US SEER population.

2 May 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NBNienke Z. Borren
Nienke Z. Borren
SGShadi Ghadermarzi
Shadi Ghadermarzi
SHSusan Hutfless
Susan Hutfless
AAAshwin N. Ananthakrishnan
Ashwin N. Ananthakrishnan
Clostridium difficile infection (CDI) is the most common healthcare associated infection and is highly prevalent in Europe and North America. Limited data is available on the prevalence of CDI in Asia. However, secular increases in prevalence of risk factors for CDI suggest that it may be emerging as a major cause of morbidity, highlighting the urgent need for a systematic study of the prevalence of CDI in Asia. We systematically searched PubMed/Medline and Embase for publications from Asia between 2000–16 examining prevalence of CDI. A random-effects meta-analysis was performed to calculate the pooled prevalence of CDI in Asia and to identify subgroups and regions at high risk. Our meta-analysis included 51 studies from throughout Asia including 37,663 patients at risk among whom confirmed CDI was found in 4,343 patients. The pooled proportion of confirmed CDI among all patients with diarrhea was 14.8% with a higher prevalence in East Asia (19.5%), compared with South Asia (10.5%) or the Middle East (11.1%). There were an estimated 5.3 episodes of CDI per 10,000 patient days, similar to rates reported from Europe and North America. Infections due to hypervirulent strains were rare. CDI-related mortality was 8.9%. In a meta-analysis of 51 studies, we observed similar rates of CDI in Asia in comparison to Europe and North America. Increased awareness and improved surveillance of Clostridium difficile is essential to reduce incidence and morbidity.

1 February 2019 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
NNNiharika Nalagatla
Niharika Nalagatla
KFKatherine Falloon
Katherine Falloon
GTGloria Tran
Gloria Tran
NBNienke Z. Borren
Nienke Z. Borren
DADanny Avalos
Danny Avalos
AAAshwin N. Ananthakrishnan
Ashwin N. Ananthakrishnan

1 March 2021 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
NBNienke Z. Borren
Nienke Z. Borren
DPDamian Plichta
Damian Plichta
AJAmit D. Joshi
Amit D. Joshi
GBGracia Bonilla
Gracia Bonilla
VPVincent Peng
Vincent Peng
AAAshwin N. Ananthakrishnan
Ashwin N. Ananthakrishnan

1 July 2017 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
NBNienke Z. Borren
Nienke Z. Borren
GCGrace Conway
Grace Conway
WTWilliam Tan
William Tan
EAElizabeth Andrews
Elizabeth Andrews
JGJohn J. Garber
John J. Garber
AAAshwin N. Ananthakrishnan
Ashwin N. Ananthakrishnan
Background. Optimal treatment of inflammatory bowel disease (IBD) requires specialized health care. Patients frequently travel long distances to obtain care fo